Search alternatives:
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
881
-
882
-
883
-
884
-
885
-
886
-
887
-
888
-
889
Table 1_Atractylenolide-I restore intestinal barrier function by targeting the S100A9/AMPK/mTOR signaling pathway.xlsx
Published 2025“…Mechanistically, recombinant human S100A9 protein was found to induce a decrease in intracellular Ca<sup>2+</sup> concentration, while AT-1 regulated the expression of tight junction proteins via modulation of the AMPK/mTOR signaling pathway. …”
-
890
Image 2_Atractylenolide-I restore intestinal barrier function by targeting the S100A9/AMPK/mTOR signaling pathway.tif
Published 2025“…Mechanistically, recombinant human S100A9 protein was found to induce a decrease in intracellular Ca<sup>2+</sup> concentration, while AT-1 regulated the expression of tight junction proteins via modulation of the AMPK/mTOR signaling pathway. …”
-
891
Image 1_Atractylenolide-I restore intestinal barrier function by targeting the S100A9/AMPK/mTOR signaling pathway.tif
Published 2025“…Mechanistically, recombinant human S100A9 protein was found to induce a decrease in intracellular Ca<sup>2+</sup> concentration, while AT-1 regulated the expression of tight junction proteins via modulation of the AMPK/mTOR signaling pathway. …”
-
892
-
893
-
894
Decreased self-renewal capacity associated with senescence was prevented in human MSCs following treatment with Ki16425, an LPA<sub>1</sub>/LPA<sub>3</sub> antagonist.
Published 2012“…Human MSCs at passage 2 were cultured in the presence or absence of Ki16425 for the indicated days prior to cell lysis. Fold-change represents decrease in band intensity of Ki16425 treatment for 18 days compared with a control treatment for the same period of time. …”
-
895
-
896
-
897
-
898
-
899
Pharmacodynamic Profile of CCX168 in Healthy Human Volunteers.
Published 2016“…CD11b upregulation was diminished in both blood samples from CCX168 subjects with a 10-fold decrease in C5a potency exhibited in the 12-hour samples.…”
-
900